Background CARs are simulated receptors containing an extracellular single-chain variable
fragment (scFv), a transmembrane domain, as well as an intracellular region of …

Immuno-oncology approaches have entered clinical practice, with tremendous progress
particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide …

Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has achieved tremendous
success treating B cell malignancies; however, some patients fail to respond due to poor …

Despite the considerable efficacy observed when targeting a dispensable lineage antigen,
such as CD19 in B cell acute lymphoblastic leukaemia,, the broader applicability of adoptive …

Chimeric antigen receptor (CAR) T cells, T cells that have been genetically engineered to
express a receptor that recognizes a specific antigen, have given rise to breakthroughs in …

PURPOSE CD19-targeted chimeric antigen receptor T cells (CD19-CAR) and blinatumomab
effectively induce remission in relapsed or refractory B-cell acute lymphoblastic leukemia …

Emerging data from chimeric antigen receptor (CAR) T-cell trials in B-cell malignancies
demonstrate that a common mechanism of resistance to this novel class of therapeutics is …

We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion
with CD19–leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was …

We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19–
relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast …

Chimeric antigen receptor (CAR) T-cell therapy is highly effective in the treatment of B-cell
acute lymphoblastic leukemia (ALL) or B-cell lymphoma, providing alternative therapeutic …